Overview

• Study analyzed health records of over 18,000 adults using tirzepatide (Mounjaro) or semaglutide (Ozempic).
• Mounjaro users lost an average of 15.3% of their body weight over 12 months, compared to 8.3% for Ozempic users.
• Patients on Mounjaro were three times more likely to achieve a 15% weight loss than those on Ozempic.
• Both drugs showed similar rates of gastrointestinal side effects, including nausea and vomiting.
• Further research is needed to compare other health outcomes like cardiovascular benefits.